Adagrasib (Everest)

💊 Product Overview

Adagrasib (Brand name: Krazati) is a targeted therapy approved for the treatment of advanced non-small cell lung cancer (NSCLC) carrying KRAS G12C mutations. It became the second KRAS G12C inhibitor approved following sotorasib and represents a major breakthrough in precision oncology.

KRAS mutations were historically considered “undruggable,” but Adagrasib has opened a new therapeutic pathway for patients with KRAS G12C-mutated tumors, including NSCLC, colorectal cancer (CRC), and other solid tumors — especially for patients whose disease has progressed after prior therapies.

🎯 Indications

Adagrasib is indicated for patients with:

• Advanced NSCLC confirmed to carry KRAS G12C mutations
• Disease progression following prior systemic therapies such as chemotherapy or immunotherapy
• Resistance or treatment failure after previous KRAS G12C inhibitor therapy (including sotorasib in some cases)
• Locally advanced or metastatic colorectal cancer (CRC) with KRAS G12C mutations when used in combination with cetuximab after standard chemotherapy

🔬 Important: KRAS G12C mutation testing is required before treatment initiation.

Approximately 13% of NSCLC patients carry KRAS G12C mutations, making it one of the more common oncogenic mutations in lung cancer.

🧬 Mechanism of Action

Adagrasib selectively binds to the KRAS G12C protein and inhibits downstream signaling pathways such as MAPK, helping block tumor cell growth and spread.

Compared with earlier KRAS G12C inhibitors, Adagrasib offers several potential advantages:

• Longer plasma half-life (~24 hours) for more stable drug exposure
• Strong tumor tissue penetration
• Activity observed in certain patients resistant to first-generation KRAS inhibitors such as sotorasib
• Potential central nervous system (CNS) activity, with preclinical and early clinical data suggesting blood-brain barrier penetration that may benefit patients with brain metastases

📊 Clinical Trial Data — KRYSTAL-1 Study

These findings demonstrated meaningful clinical benefit for patients with KRAS G12C-positive NSCLC.

💊 Dosage and Administration

• Recommended dosage: 600 mg orally twice daily
• May be taken with or without food
• Take doses at approximately the same time each day

Missed Dose Guidance

• If a dose is missed and more than 6 hours remain before the next scheduled dose, the missed dose may be taken
• If less than 6 hours remain before the next dose, skip the missed dose and continue the normal schedule

⚠️ Common Side Effects

Common adverse reactions may include:

• Nausea
• Diarrhea
• Reduced appetite
• Elevated liver enzymes (ALT/AST)
• Fatigue and weakness

Rarely, QT interval prolongation may occur, and periodic ECG monitoring may be recommended.

📦 Packaging & Storage

• Strength: 200 mg tablets
• Packaging: 42 tablets per bottle (approximately 7 days of therapy)
• Storage: Store at room temperature away from direct sunlight and moisture

📋 Treatment Considerations